preloader
- 16 March 2022 -

Olaparib approved for US patients with early-stage hereditary breast cancer

 


BIG is delighted that the second interim analysis of OlympiA trial building on the earlier published results (NEJM) will lead to fewer deaths among patients with germline BRCA-mutated (gBRCA) breast cancer, as the U.S. Food and Drug Administration has just announced approval of olaparib for gBRCA breast cancer patients who have had chemotherapy, and the full details of the data will be presented during an ESMO Virtual Plenary session at 6.30 PM (CET) on 16 March.

 

OlympiA is a global clinical trial that enrolled a total of 1,836 patients from over 600 hospitals and cancer centres in 23 countries worldwide.

The study is coordinated by the Breast International Group (BIG), in partnership with NRG Oncology, the US National Cancer Institute (NCI), Frontier Science & Technology Research Foundation (FSTRF), AstraZeneca and MSD. The trial is sponsored by NRG Oncology in the US and by AstraZeneca outside the US.

Read more about the OlympiA study